Marinomed Biotech Ag · VIE:MARI
Marinomed Biotech — Q1 2023 Earnings Presentation
21 slides from Marinomed Biotech's earnings presentation, May 23, 2023
Slide 1: Investor Presentation Q1 2023
Investor Presentation Q1 2023 Andreas Grassauer, CEO Pascal Schmidt, CFO Korneuburg, May 23rd, 2023
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) was prepared by Marinomed Biotech AG. The information contained in this Presentation has not been independently verified and no representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy
Slide 3: Agenda
Agenda • Highlights Q1 2023 Andreas Grassauer, CEO • Financials Q1 2023 Pascal Schmidt, CFO • Marinomed growth strategy for Virology Andreas Grassauer, CEO and Immunology segment • Project outlook • Financial calendar, contact © Marinomed Biotech AG 3
Slide 4: Highlights Q1 2023
Highlights Q1 2023 Progress and execution EUR 3.3 m + 38% USA Trials Increase in Preparation New clinical data Financial outlook for Carragelose for market entry with support expansion to FY2023 confirmed revenues Procter & Gamble allergy © Marinomed Biotech AG 4
Slide 5: Agenda
Agenda • Highlights Q1 2023 Andreas Grassauer, CEO • Financials Q1 2023 Pascal Schmidt, CFO • Marinomed growth strategy for Virology Andreas Grassauer, CEO and Immunology segment • Project outlook • Financial calendar, contact © Marinomed Biotech AG 5
Slide 6: Continuous double digit growth
Continuous double digit growth Strong Carragelose business and positive outlook Y-o-Y comparison of quarterly revenues (m€) Comments Key growth drivers 5.9* 4.1 • Revenues rose from €2.4m to €3.3m (+37.6%) in Q1 3.3 2023 2.5 2.5 2.2 2.4 1.0 New business Q2 Q2 Q3 Q3 Q4 Q4 Q1 Q1 • Continued regulatory
Slide 7: Solid cash position
Solid cash position Q1 cashflow primarily impacted by partial repayment of EIB1 loan and profitable revenues • 12 months period starts with €11.7m in cash • Raised +€1.2m cash through CNFP2 • Earned +€4.8m net cash through profitable sale of goods • Repaid -€1.5m debt incl. interest to EIB, WAW3 and
Slide 8: Q1 statement of profit or loss (IFRS)
Q1 statement of profit or loss (IFRS) Strongest Q1 in the history of Marinomed €m Q1 2023 Q1 2022 •1 Therein: Q1 2023 Q1 2022 Revenues 1 3.3 2.4 Sale of goods 3.2 2.4 Other income 2 0.1 0.1 Cost of goods sold -2.1 -1.5 Materials expenses -2.2 -1.5 Margin 32.7% 33.1% Services expenses 3 -0.7 -0.4 •2
Slide 9: Q1 2023 Statement of financial position (IFRS)
Q1 2023 Statement of financial position (IFRS) Assets €m Q1 2023 FY 2022 1 Inventories €m Q1 2023 FY 2022 Assets Goods for sale 0.1 0.2 Intangible assets 1.7 1.8 Unfinished goods 0.4 0.4 Property, plant and equipment 6.2 6.2 Raw materials 0.9 0.9 Deposits and other non-current Total inventories 1.3
Slide 10: Q1 2023 Statement of financial position (IFRS)
Q1 2023 Statement of financial position (IFRS) Equity and liabilities €m Q1 2023 FY 2022 •1 Capital increases through convertible note funding program Equity and liabilities Share capital 1.5 1.5 •2 Primarily related to EIB loan (€15.0m1) as well as ERP/aws Capital reserves 1 44.7 44.1 and NÖBEG rea
Slide 11: Agenda
Agenda • Highlights Q1 2023 Andreas Grassauer, CEO • Financials Q1 2023 Pascal Schmidt, CFO • Marinomed growth strategy for Virology Andreas Grassauer, CEO and Immunology segment • Project outlook • Financial calendar, contact © Marinomed Biotech AG 11
Slide 12: Therapeutic Areas
Therapeutic Areas Proven track record with clinically validated and patent protected technologies VIROLOGY IMMUNOLOGY • Iota-carrageenan from red seaweed: • Marinosolv technology: solubilization for broad-spectrum virus blocker hydrophobic compounds • Clinically validated efficacy against Suspension
Slide 13: Marinomed strategic priorities
Marinomed strategic priorities Focus on revenue generation with existing products and product candidates INHALEEN • Long-term adherence to our mission MAM-1004-2 • Funding promising pipeline programs through own cash flows NEW ASSETS FOR ADDITIONAL GROWTH TACROSOLV BUDESOLV • Expanding business with
Slide 14: Pipeline
Pipeline Late-stage projects partnering processes – high upside potential © Marinomed Biotech AG 14
Slide 15: Carragelose – growth strategy
Carragelose – growth strategy Expansion of territory, indication and product portfolio Target Action item Status / next steps USA -> FDA registration USA (Procter & Gamble), Mexico Territory expansion - registration Mexico -> approval expected soon and Brazil (M81) Brazil -> ANVISA registration Focu
Slide 16: Immunology – focus on business development
Immunology – focus on business development Expansion of territory, indication and product portfolio Area / Product Action item Status / next steps Complete the BD process and Tacrosolv (MAM-1003-1) Run a structured BD process with enable a partnership within the next Inflammatory eye diseases extern
Slide 17: Project status updates
Project status updates Project Status/next steps Tacrosolv Enter into a partnership within the next 9-18 months Immunology Budesolv Work on registration with Luoxin for Greater China; additional partnership for Europe (6-12 months) Autoimmune gastritis Preclinical research; apply for FFG1 grant Carr
Slide 18: Outlook
Outlook Continue Strategy 2025 with focus on near-term revenues • Strengthen existing business • Drive Carragelose in the U.S., Mexico and others and partnerships to ensure • Capitalize on recently published positive clinical data on allergy sustainable revenue growth • Support Luoxin to move to IND
Slide 19: Agenda
Agenda • Highlights Q1 2023 Andreas Grassauer, CEO • Financials Q1 2023 Pascal Schmidt, CFO • Marinomed growth strategy for Virology Andreas Grassauer, CEO and Immunology segment • Project outlook • Financial calendar, contact © Marinomed Biotech AG 19
Slide 20: Financial calendar & IR contact
Financial calendar & IR contact Financial Calendar 2023 Record Date for participation June 11, 2023 at the Annual General Meeting June 21, 2023 6th Annual General Meeting August 17, 2023 Publication of the Results H1 2023 November 21, 2023 Publication of the Results Q1-3 2023 Stephanie Kniep Investo
Slide 21: www.marinomed.com
www.marinomed.com Q? Marinomed